- Conditions
- Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb Girdle Muscular Dystrophy
- Interventions
- Not listed
- Lead sponsor
- Cooperative International Neuromuscular Research Group
- Network
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 10,399
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Immune Deficiency
- Interventions
- IgPro20
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 2 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 4
- States / cities
- Centennial, Colorado • North Palm Beach, Florida • Indianapolis, Indiana + 1 more
- Conditions
- Anemia, Sickle Cell
- Interventions
- ICL670, deferoxamine
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 34
- States / cities
- Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more
- Conditions
- Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
- Interventions
- LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
- Biological
- Lead sponsor
- Abeona Therapeutics, Inc
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Smith-Magenis Syndrome (SMS)
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Month to 115 Years
- Enrollment
- 593 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hereditary Hemochromatosis
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 21 Years to 100 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Congenital Anomaly, Pediatric Cancer
- Interventions
- Whole Genome Sequencing, Questionnaire Administration, Biospecimen collection, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 0 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Patent Ductus Arteriosus (PDA)
- Interventions
- Device closure with AMPLATZER Duct Occluder, Objective Performance Criteria
- Device · Other
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 436 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • San Diego, California • Denver, Colorado + 21 more
- Conditions
- Cytomegalovirus Infections, HIV Infections
- Interventions
- Zidovudine, Didanosine, Ganciclovir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 3
- States / cities
- Irvine, California • Washington D.C., District of Columbia • Galveston, Texas
- Conditions
- Huntington Disease, Huntington's Dementia, Huntington Disease, Late Onset, Huntington; Dementia (Etiology)
- Interventions
- Biospecimen Collection
- Other
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 5 participants
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Woburn, Massachusetts
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- TN-201
- Genetic
- Lead sponsor
- Tenaya Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 10
- States / cities
- La Jolla, California • San Francisco, California • Atlanta, Georgia + 7 more
- Conditions
- Erythropoietic Protoporphyria, EPP, X-Linked Protoporphyria, XLP, XLPP, X-Linked Dominant Erythropoietic Protoporphyria, XLEPP, XLDP
- Interventions
- Not listed
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
- Conditions
- Spinal Muscular Atrophy 1
- Interventions
- Onasemnogene Abeparvovec-xioi
- Biological
- Lead sponsor
- Novartis Gene Therapies
- Industry
- Eligibility
- Not listed
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2030
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Congenital Heart Defects
- Interventions
- Not listed
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Mild Autonomous Cortisol Secretion (MACS)
- Interventions
- Osilodrostat (Isturisa)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pompe Disease (Late-Onset), Glycogen Storage Disease Type II (GSD-II), Glycogenesis Type II, Acid Maltase Deficiency (AMD)
- Interventions
- alglucosidase alfa
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 26
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Beverly Hills, California + 23 more
- Conditions
- Chronic Rhinosinusitis (Diagnosis), Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Stanford, California • Aurora, Colorado + 6 more
- Conditions
- Intercritical Gout
- Interventions
- Colchicine (Colcrys®), placebo, allopurinol
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 37
- States / cities
- Alabaster, Alabama • Mesa, Arizona • Upland, California + 34 more
- Conditions
- Epilepsy
- Interventions
- retigabine/ezogabine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years to 29 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Wellington, Florida • Memphis, Tennessee + 1 more
- Conditions
- LMNA-Related Dilated Cardiomyopathy
- Interventions
- ARRY-371797, p38 inhibitor, oral
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Respiratory Distress Syndrome, Newborn, Pulmonary Surfactants, Intensive Care Units, Neonatal
- Interventions
- Echography-guided Surfactant THERapy (ESTHER)
- Diagnostic Test
- Lead sponsor
- Connecticut Children's Medical Center
- Other
- Eligibility
- 0 Hours to 2 Hours
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Sickle Cell Disease, Vaso-Occlusive Crisis
- Interventions
- Ketamine
- Drug
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Cerebral Palsy, Neurologic Disorder, Chromosome Abnormality, Spina Bifida
- Interventions
- Lite Run Gait Trainer, Usual Treatments
- Device · Other
- Lead sponsor
- Gillette Children's Specialty Healthcare
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Urologic Diseases, Male Urogenital Diseases, Penile Diseases, Corpus Callosum Malformation, Corpora Cavernosa; Inflammation, Trauma Injury
- Interventions
- Autologous tissue engineered corpora
- Biological
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina